Asset profile
Palazestrant
Small molecule
Evidence outlook · registrational
HR+/HER2- Metastatic Breast Cancer: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-10-31.
NCT04505826: The study was nonrandomized, unblinded, and single-arm, with participants receiving OP-1250 at sequential dose levels and no placebo or active comparator. Its results were descriptive rather than a formal comparative test: dose-limiting toxicities were 0/42 during dose escalation, while confirmed partial responses included 4/62 participants at 120 mg once daily; therefore, the primary outcomes were not formally met or missed against a control.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 29 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Palazestrant: this drug | Phase 3 | Small molecule | Estrogen receptor | ||
| Elacestrant | Approved | Small molecule | Estrogen receptor | ||
| Fulvestrant (Faslodex) | Approved | Small molecule | Estrogen receptor | ||
| Imlunestrant | Approved | Small molecule | Estrogen receptor | ||
| Tamoxifen | Approved | Small molecule | Estrogen receptor | ||
| Vepdegestrant | Approved | Small molecule | Estrogen receptor | ||
| Camizestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Giredestrant | Phase 3 | Small molecule | Estrogen receptor | ||
| Abemaciclib (Verzenio) | Approved | Small molecule | CDK4 and CDK6 | ||
| Alpelisib (BYL719) | Approved | Small molecule | PI3K-alpha | ||
| Anastrozole | Approved | Small molecule | Aromatase | ||
| Capecitabine | Approved | Small molecule | Fluoropyrimidine (antimetabolite) | ||
| Capivasertib | Approved | Small molecule | AKT (inhibitor) | ||
| Datopotamab Deruxtecan | Approved | Antibody–drug conjugate | TROP2 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Docetaxel | Approved | Small molecule | Microtubules (tubulin) |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
October 2026 (1)
What to watch
2027 (1)
December 2027 (1)
What to watch
2028 (1)
December 2028 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.